Immix Biopharma Inc. has published a presentation highlighting its work in the treatment of relapsed/refractory AL amyloidosis. The presentation details the significant unmet need for therapies in this condition, noting that approximately 38,500 patients in the U.S. face limited treatment options and there are currently no drugs approved for relapsed/refractory AL amyloidosis. The company's investigational therapy, NXC-201, targets plasma cells expressing the BCMA receptor, aiming to eliminate the source of harmful light chains that contribute to organ damage in affected patients. Data presented include clinical outcomes and disease markers, emphasizing the challenges faced by patients and the potential impact of new targeted therapies. You can access the full presentation through the link below.